)
Visual24 Oct 2025
The rise of Alphabet
MBX Biosciences (MBX) investor relations material
MBX Biosciences Stifel Virtual Cardiometabolic Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Stifel Virtual Cardiometabolic Forum summary30 Sep, 2025
Key program updates
Positive phase II results for once-weekly Canvuparatide in hypoparathyroidism showed a 79% responder rate at six months, surpassing the 69% rate of the once-daily injectable comparator.
All patients completed the Canvuparatide trial, with 94% enrolling in a two-year extension, and no treatment-related serious adverse events or discontinuations were observed.
Phase III registration study for Canvuparatide is planned, with dose selection focused on balancing efficacy and minimizing hypercalcemia during titration.
MBX 1416, a GLP-1 antagonist for post-bariatric hypoglycemia, demonstrated a long half-life and promising pharmacodynamic signals in phase I, with phase II-A data expected next year.
MBX 4291, an ultra-long-acting GLP-1/GIP co-agonist, is in phase I for obesity, aiming for once-monthly dosing and improved tolerability, with preclinical data showing strong weight loss and safety.
Platform and pipeline strategy
Precision Endocrine Peptide (PEP) platform enables best-in-class, long-acting peptide therapeutics with blockbuster potential.
Obesity portfolio includes MBX 4291 and additional candidates in lead optimization, leveraging continuous infusion-like drug exposure for improved tolerability.
The company is considering strategic partnerships for large-scale obesity programs due to the need for extensive registration studies and sales forces.
The pipeline is constructed to address validated and emerging targets in obesity, with a focus on best-in-class profiles and precision medicine.
Strong cash position of $412 million as of June 30, 2025, expected to fund operations into 2029 and support key milestones across the pipeline.
Clinical differentiation and future outlook
Canvuparatide aims to differentiate through reduced urinary calcium excretion, a potential label advantage if confirmed in phase III.
MBX 4291’s once-monthly dosing and flat pharmacokinetic profile are designed to improve adherence, tolerability, and weight loss durability.
MBX 1416 targets an unmet need in post-bariatric hypoglycemia, with a mechanism and dosing profile tailored for full day and night coverage.
No weight gain or significant glucose increases observed with MBX 1416 in preclinical or phase I studies.
End of phase II meeting for Canvuparatide is planned for Q4, with updates on global phase III study design and timelines to follow.
How does MBX 4291's PK profile drive market leadership?
What clinical advantage does 1416's long half-life offer?
What label differentiation is sought for Kaniparutide?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next MBX Biosciences earnings date
Q3 20256 Nov, 2025
Next MBX Biosciences earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
MBX Biosciences Inc. is a U.S.-based biotechnology company focused on developing precision medicines for endocrine disorders. The company’s research and development efforts target rare hormonal conditions, with a focus on creating peptide therapies that improve patient outcomes. Leveraging proprietary technology, MBX Biosciences aims to design therapies that address specific needs in endocrinology, including disorders related to hormone deficiencies or imbalances. The company advances its drug candidates through preclinical and clinical stages, seeking to bring effective treatments to patients with unmet medical needs. The company is headquartered in Carmel, Indiana, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage